- Tropical spastic paraparesis
Name = PAGENAME
DiseasesDB = 29487
ICD10 = ICD10|G|04|1|g|00
eMedicineSubj = med
eMedicineTopic = 1038
MeshID = D015493
Tropical spastic paraparesis (TSP) is an
infectionof the spinal cordby Human T-lymphotropic virusresulting in paraparesisor weakness of the legs. As the name suggests, it is most common in tropicalregions, including the Caribbeanand Africa.
For several decades the term tropical spastic paraparesis was used to describe a chronic and progressive clinical syndrome that affected adults living in equatorial areas of the world. This condition was initially thought to be associated with infectious agents (such as
Treponema pertenueand Treponema pallidumwhich cause inflammation of the central nervous system) and with chronic nutritional deficiencies (such as avitaminosis) or exposure to potentially toxic foods (such as bitter cassava). Neurological and modern neuroepidemiological studies found that in some individuals no single cause could explain the progressive weakness, sensory disturbance, and sphincter dysfunction that affected individuals with TSP. In spite of public health programs created to eradicate the above-mentioned infectious and nutritional conditions in the tropics, large numbers of people continued to be affected.
During the mid-1980s, an important association was established between the first human retrovirus-human T-cell lymphotrophic virus type 1 (also known as
HTLV-1)-and idiopathic TSP (idiopathic means of unknown origin). Since then, this condition has been named HTLV-1 associated myelopathy/ tropical spastic paraparesis or HAM/TSP and scientists now understand that it is a condition caused by a virusthat results in immune dysfunction.
Patients with HAM/TSP may also exhibit
uveitis(inflammation of the uveal tract of the eye), arthritis(inflammation of one or more joints), pulmonary lymphocytic alveolitis (inflammation of the lung tissues), polymyositis(an inflammatory muscle disease), keratoconjunctivitis sicca(persistent dryness of the cornea and conjunctiva), and infectious dermatitis (inflammation of the skin). Co-factors that may play a role in transmitting the disorder include being a recipient of transfusion blood products (especially before 1989), breastmilk feeding from a seropositivemother, intravenous druguse, or being the sexual partner of a seropositive individual for several years. Not every HTLV-1 seropositive carrier will become a HAM/TSP patient. Fewer than 5% will exhibit neurological dysfunction or, eventually, hematological malignancy such as adult T-cell leukemia/lymphoma, suggesting that other host or viral factors are responsible for disease onset.
When infected by
HTLV-1the host mounts an antigen specific immune response towards the HTLV-1antigen. Cytotoxic T-lymphocytesof the host’s immune response release cytokinesin an effort to fight the infection. These cytokinesfacilitate the transendothelial migration of lymphocytesacross the blood-brain barrier. Once cytokinesare within the central nervous system demyelination is brought as a result of bystander cell injury. The disease is chronic, progressing slowly, usually causing symptoms 20-30 years after infection.
* Progressive muscle weakness;
* Sensory disturbance
* Pulmonary lymphocyte alveolitis
Blood transfusion products are screened for
There is no established treatment program for HAM/TSP although some patients may be given
steroids. Clinical studies using interferon alpha and plasmapheresishave not shown significant patient improvement. Spasticitymay be treated with lioresalor tizanidine. Urinary dysfunction should be treated with self-catheterization or oxybutynin.
HAM/TSP is usually a progressive neurological disorder but it is rarely fatal. Most patients live for several decades after the diagnosis. Their prognosis improves if they take steps to prevent urinary tract infection and skin sore formation, and if they enroll in physical and occupational therapy programs.
Wikimedia Foundation. 2010.